Company news: Forest Labs, Novartis and Pfizer

Share this article:
Forest Labs said its CEO will challenge a US Department of Health and Human Services attempt to exclude him from participation in federal healthcare programs. HHS notified CEO Howard Solomon of the potential action yesterday by letter, the company said, adding that the missive alleges no wrongdoing and stems from matters the company settled last year. In September Forest paid $313 million and agreed to plead guilty to a felony obstruction of justice charge, and two misdemeanor counts related to the distribution of an unapproved drug—Levothroid—and the misbranding or off-label promotion of two anti-depressants, Lexapro and Celexa. Solomon, who was given 30 days to respond to HHS, would have to step down from his present executive positions if the HHS decides to exercise its exclusion authority.

An FDA advisory panel voted in favor of approving drugs from Pfizer and Novartis for pancreatic neuroendocrine tumors (pNET). The drugs, Afinitor from Novartis and Sutent from Pfizer, are already on the market for treating kidney cancer. Regulatory decisions on the pNET indications are likely to come in late 2011.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.